Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € ↓ -0,05 (-2,59%)
2026-06-03
DEL PRIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership22,295 shares
Latest Disclosed Value $ 62,203
Citigroup Inc reports 98.62% increase in ownership of PHPN / Galectin Therapeutics Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 22,295 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $49,941 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 11,225 shares of Galectin Therapeutics Inc.. This represents a change in shares of 98.62% during the quarter. The current value of the position is $41,915 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 22,295 11,070 98.62 62 34.78 0.0000
2026-02-13 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 11,225 11,089 8,153.68 47 0.0000
2025-11-10 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 136 94 223.81 1 0.0000
2025-08-11 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 42 -6,565 -99.36 0 -100.00 0.0000
2025-05-12 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 6,607 -9,467 -58.90 8 -60.00 0.0000
2025-02-12 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 16,074 1,330 9.02 21 -50.00 0.0000
2024-11-12 2024-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 14,744 10,259 228.74 41 300.00 0.0000
2024-08-12 2024-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 4,485 4,485 10 0.0000
2024-05-10 2024-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 0 -10,650 -100.00 0 -100.00
2024-02-09 2023-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 10,650 10,650 18 0.0000
2021-11-10 2021-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 0 -557 -100.00 0 -100.00
2021-08-10 2021-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 557 -1,905 -77.38 2 -60.00 0.0000
2021-05-13 2021-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 2,462 -4,992 -66.97 5 -70.59 0.0000
2021-02-11 2020-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 7,454 5,667 317.12 17 240.00 0.0000
2020-11-12 2020-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 1,787 -3,476 -66.05 5 -68.75 0.0000
2020-08-12 2020-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 5,263 -6,932 -56.84 16 -33.33 0.0000
2020-05-12 2020-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 12,195 4,166 51.89 24 4.35 0.0000
2020-02-12 2019-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 8,029 5,842 267.12 23 187.50 0.0000
2019-11-08 2019-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 2,187 -6,847 -75.79 8 -78.38 0.0000
2019-08-12 2019-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 9,034 -49,339 -84.52 37 -87.58 0.0000
2019-05-13 2019-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 58,373 58,373 298 0.0003
2016-08-12 2016-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 0 -191 -100.00 0 0.0000
2016-05-13 2016-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 191 -1,134 -85.58 0 -100.00
2016-02-12 2015-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 1,325 1,325 0.00 2 0.0000
2015-08-13 2015-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 0 -1,098 -100.00 0 -100.00
2015-05-14 2015-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 1,098 -2,134 -66.03 4 -63.64 0.0000
2015-02-17 2014-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 3,232 1,284 65.91 11 10.00 0.0000
2014-11-14 2014-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 1,948 1,796 1,181.58 10 400.00 0.0000
2014-08-14 2014-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 152 -279 -64.73 2 -71.43 0.0000
2014-05-15 2014-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 431 195 82.63 7 250.00 0.0000
2014-02-14 2013-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 236 236 2 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.